[go: up one dir, main page]

AR127281A1 - Dendrones peptídicos y métodos de uso de los mismos - Google Patents

Dendrones peptídicos y métodos de uso de los mismos

Info

Publication number
AR127281A1
AR127281A1 ARP220102719A ARP220102719A AR127281A1 AR 127281 A1 AR127281 A1 AR 127281A1 AR P220102719 A ARP220102719 A AR P220102719A AR P220102719 A ARP220102719 A AR P220102719A AR 127281 A1 AR127281 A1 AR 127281A1
Authority
AR
Argentina
Prior art keywords
dendrons
peptide
methods
therapy
formula
Prior art date
Application number
ARP220102719A
Other languages
English (en)
Inventor
Morgan Audrey Urello
Ronald James Christie
Hannah Vaughan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR127281A1 publication Critical patent/AR127281A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La memoria descriptiva se refiere a dendrones peptídicos que comprenden uno o más residuos derivados de una lisina modificada de fórmula (1), a sistemas de administración farmacéutica que comprenden estos dendrones peptídicos, a composiciones farmacéuticas que los contienen, y a su uso en terapia.
ARP220102719A 2021-10-08 2022-10-06 Dendrones peptídicos y métodos de uso de los mismos AR127281A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163262269P 2021-10-08 2021-10-08

Publications (1)

Publication Number Publication Date
AR127281A1 true AR127281A1 (es) 2024-01-03

Family

ID=83995423

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102719A AR127281A1 (es) 2021-10-08 2022-10-06 Dendrones peptídicos y métodos de uso de los mismos

Country Status (19)

Country Link
US (1) US20240408220A1 (es)
EP (1) EP4412662A1 (es)
JP (1) JP2024537869A (es)
KR (1) KR20240082404A (es)
CN (1) CN118119411A (es)
AR (1) AR127281A1 (es)
AU (1) AU2022361764A1 (es)
CA (1) CA3233268A1 (es)
CL (1) CL2024001024A1 (es)
CO (1) CO2024005252A2 (es)
CR (1) CR20240185A (es)
DO (1) DOP2024000066A (es)
EC (1) ECSP24035412A (es)
IL (1) IL311853A (es)
MX (1) MX2024004334A (es)
PE (1) PE20241473A1 (es)
TW (1) TW202342497A (es)
UY (1) UY39976A (es)
WO (1) WO2023057975A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2661289A1 (en) * 2006-08-17 2008-10-09 Zheng-Rong Lu Dendrimers and methods of making and using thereof
WO2011116152A2 (en) * 2010-03-16 2011-09-22 Sanford -Burnham Medical Research Institute Delivery of agents using interfering nanoparticles
WO2012016139A2 (en) * 2010-07-29 2012-02-02 Sirnaomics, Inc. Sirna compositions and methods for treatment of hpv and other infections
US9745421B2 (en) * 2013-03-20 2017-08-29 The Regents Of The University Of California Dendronized polymers for nucleic acid delivery
US20220340899A1 (en) * 2019-08-07 2022-10-27 Universität Bern Stereoselective ph responsive peptide dendrimers for nucleic acid transfection
MX2023004104A (es) * 2020-10-09 2023-06-29 Sumitomo Pharma Co Ltd Conjugado de acido oligonucleico.
CA3214023A1 (en) * 2021-04-02 2022-10-06 Poulami TALUKDER Dendritic architectures as nonviral vectors in gene delivery

Also Published As

Publication number Publication date
CL2024001024A1 (es) 2024-10-11
AU2022361764A1 (en) 2024-05-16
CN118119411A (zh) 2024-05-31
MX2024004334A (es) 2024-04-24
DOP2024000066A (es) 2024-05-31
CA3233268A1 (en) 2023-04-13
ECSP24035412A (es) 2024-06-28
KR20240082404A (ko) 2024-06-10
WO2023057975A1 (en) 2023-04-13
JP2024537869A (ja) 2024-10-16
US20240408220A1 (en) 2024-12-12
PE20241473A1 (es) 2024-07-17
UY39976A (es) 2023-04-14
CR20240185A (es) 2024-06-11
CO2024005252A2 (es) 2024-05-10
EP4412662A1 (en) 2024-08-14
TW202342497A (zh) 2023-11-01
IL311853A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CO2020010303A2 (es) Conjugados de il-15, y sus usos
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
BR112022001897A2 (pt) Composições de higiene pessoal
FI964285A0 (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
EA202192925A1 (ru) Твердые формы ингибитора glyt1
CO2022001050A2 (es) Novedosos conjugados de il–15 y sus usos
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
MX2023013515A (es) Inhibidores de la interaccion de menina-mll.
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
ES2066510T3 (es) Nuevos polipeptidos con afinidad para lipopolisacaridos y sus usos.
CO2023012342A2 (es) Inhibidores de enzimas
CO2022000575A2 (es) Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
MX2024009773A (es) Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.
AR127281A1 (es) Dendrones peptídicos y métodos de uso de los mismos
ECSP22090761A (es) Composiciones y métodos para suministrar agentes farmacéuticamente activos
TR200103240T2 (tr) Endoparazit öldürücü bileşimler.
DOP2021000028A (es) Formulaciones de dendrímeros
BR112023019917A2 (pt) Uso de uma composição farmacêutica
PL431336A1 (pl) Lipopeptydy, kompozycja farmaceutyczna, kompozycja kosmetyczna oraz lipopeptydy do zastosowania jako lek